Analysis of drug consumption from the group of angiotensin II receptor blockers in the Republic of Serbia in the period 2012-2021

Introduction: High blood pressure is the leading factor in the development of cardiovascular diseases and premature death of patients worldwide. Angiotensin II receptor blockers (ARBs) have been proven to be highly effective in both lowering arterial hypertension and preventing cardiovascular outcomes. Aim: The aim of this study was to analyze the consumption of drugs from the group of angiotensin II receptor blockers in the Republic of Serbia in the period from 2012 to 2021, as well as to examine the relationship between the price of these medications and their consumption. Material and Method: Drug consumption was monitored using the ATC/DDD methodology, as well as using the DU 90% method. The connection between drug consumption and price was examined by linear regression at the level of statistical significance of 0.05. Results: Analyzing the consumption of the examined group of drugs, the most prescribed ones include valsartan, losartan, telmisartan, irbesartan, as well as their combinations with hydrochlorothiazide. Compared to Finland and Norway, the consumption of these medications was two to twelve times higher than in our country. Since 2018, the combination of valsartan-sacubitril drugs has been present in Serbia, and the expenditure on this fixed combination has been continuously increasing. Conclusion: The consumption of ARB drugs is increasing and shows a negative correlation with their price. Due to their better efficiency, reduced toxicity and faster achievement of the therapeutic goal, preference should be given to fixed doses of these drugs rather than monocomponents.